Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Table 2 Distribution of changes in time-intensity curve parameters in tumors from day 0 to day 7 for 20 hepatocellular carcinoma patients according to modified Response Evaluation Criteria in Solid Tumors response at 2 mo
Responders (n = 9) | Non-responders (n = 11) | |||
Day 0 | Day 7 | Day 0 | Day 7 | |
Slope | 1.51 [1.31, 1.68] | 1.09 [0.84, 1.23] | 1.52 [1.22, 1.62] | 1.33 [0.86, 1.71] |
P value | 0.018 | 0.511 | ||
TTP | 10.56 [9.33, 12.13] | 12.43 [11.94, 13.94] | 11.02 [8.53, 12.51] | 11.84 [10.15, 13.82] |
P value | 0.003 | 0.247 | ||
AUC | 266.51 [225.38, 296.67] | 156.44 [123.05, 178.91] | 258.14 [191.61, 299.51] | 229.65 [176.10, 269.50] |
P value | 0.001 | 0.322 |
- Citation: Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2365